Skip to main content
  1. Right Decisions
  2. Back
  3. Breast pathways
  4. Gynaecomastia
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Gynaecomastia

Warning

The Gynaecomastia Pathway includes recommendations for management in primary care and in the breast unit.

Click the play button below to find out more about about breast lesions in men.

 

Background

The Symptomatic Breast Speciality Delivery Group was established to support and look at new innovative ways to delivering Symptomatic Breast services across NHS Scotland.

Through development of Once for Scotland approaches for delivery of care, focus is being placed on looking at opportunities to develop clinical pathways to reduce unwarranted variation in delivery of quality healthcare and to sustainably improve waiting times for non-urgent care within breast services.

Speciality Delivery Groups have been established to engage and fully utilise the role of clinical leadership across NHS Scotland.

Development of the Gynaecomastia Pathway has been progressed through the Symptomatic Breast Speciality Delivery Group.

The recommendations have not followed the standard process used by the Scottish Intercollegiate Guidelines Network (SIGN) but are based on available guidance and expert opinion, with peer review to provide quality assurance.

This guidance will be reviewed and updated as new evidence emerges.

 

Definition

Gynaecomastia is a benign enlargement of the male breast with firm tissue extending concentrically beyond the nipple. It may unilateral, bi-lateral, painful or asymptomatic4.

 

Consensus

A common theme during the Breast Speciality Delivery group meetings has focused on the referral of men with breast issues to secondary care services.

A consensus was formed around the principles that:

  1. Gynaecomastia is a breast manifestation of a systemic problem. Secondary care referral and investigation is not necessary in the vast majority of cases and variation in practice and over investigation are common.
  2. Breast lumps in men (rather than generalised swelling of the breast tissue) require specific investigation.

 

Pathway recommendations 1. Management in primary care

Examination

Should distinguish between general swelling of the breast tissue or a specific lump. Swelling of breast tissue due to gynaecomastia is often asymmetrical. A soft, well-defined lump away from the breast tissue is likely to be a lipoma and may not require further investigation, especially if other lipomas are present. A specific lump within the breast tissue (rather than generalised breast swelling) or other features of concern (such as nipple inversion, nipple discharge or distortion) requires referral to the breast unit.

History

Should be taken for causes of gynaecomastia, including drugs (prescribed or otherwise), alcohol, protein supplements, liver disease, testicular issues and obesity (see Systemic conditions associated with gynaecomastia). In those going through puberty or the very old, gynaecomastia is likely to be due to normal, age-related hormonal changes. Drugs causing gynaecomastia include antioestrogens, spironolactone, calcium channel blockers, proton pump inhibitors, cimetidine, allopurinol, digoxin, opioids, anabolic steroids and cannabis. The use of protein supplements also appears to be associated. Testicular examination should be performed for atrophy, absence or lump. If any predisposing cause is identified this should be addressed. Gynaecomastia is likely to persist or recur after treatment if the underlying cause is still present. Pubertal gynaecomastia will usually resolve spontaneously but can take many months.

Blood tests

In the absence of a predisposing cause, consider blood tests for urea and electrolytes, liver function tests, Luteinizing hormone, Follicle Stimulating Hormone testosterone, prolactin, beta human chorionic gonadotropin- and alpha-fetoprotein and thyroid function tests and address any abnormalities.

Medical treatment

Consider medical treatment for persisting pubertal gynaecomastia or where there is no obvious predisposing cause or abnormality of blood tests. This is an unlicensed indication. It is most useful for recent onset gynaecomastia and usually improves breast sensitivity. If prescription of a medication out with it's licensed indication is being considered discussion with secondary care colleagues is an option should this be felt necessary for the small number of patients who may benefit.

  • Tamoxifen 10mg once daily for 3-9 months
  • Anastrozole 1mg daily for 3 months

Surgical excision

For cosmesis is considered through the exceptional aesthetic referral pathway.

 

Pathway recommendations 2. Management in the breast unit

  • Those with a breast lump (not just generalised breast swelling) should undergo triple assessment. Those with a clinically obvious lipoma may not need further investigation.

  • Investigation and treatment pathways are otherwise as noted above for primary care.

  • When an obvious cause of gynecomastia is present, further investigation is not necessary.

  • Consider mammography in those over 40. Ultrasound scanning is not required unless a specific breast lump (not just generalised breast swelling or a lipoma) is present.

Systemic conditions associated with gynaecomastia

  • Testicular failure
  • Liver disease
  • Obesity
  • Renal failure
  • Adrenal disease
  • Hyperthyroidism
  • Testicular cancer
  • Lung cancer
  • Klinefelter’s syndrome

 

References

  1. Association of Breast Surgery (2021) Investigation and management of gynaecomastia in primary and secondary care Last accessed 22 August 2023
  2. Royal College or Radiologists (2019) Guidance on screening and symptomatic breast imaging, Fourth edition Last accessed 22 August 2023
  3. Thiruchelvam P, Churchill W, Walker JN, Rose K, Lewis J, Al-Mufti R. Gynaecomastia. BMJ 016;354:i4833 https://doi.org/10.1136/bmj.i4833
  4. Niewoehner, CB. Gynaecomastia. BMJ Best Practice. Oct 2022. https://bestpractice.bmj.com/topics/en-gb/869 Last accessed 22 August 2023

 

   gjnh.cfsdpmo@gjnh.scot.nhs.uk

  www.nhscfsd.co.uk

@NHSScotCfSD

Centre for Sustainable Delivery

  Scan the code to visit our website

Editorial Information

Last reviewed: 19/12/2024

Next review date: 01/03/2026

Author(s): Symptomatic Breast Speciality Delivery Group.

Approved By: Centre for Sustainable Delivery

Reviewer name(s): Centre for Sustainable Delivery.